Why the study?
Endocan is a novel immunoinflammatory marker potentially associated with cardiometabolic risk factors, but its levels in newly diagnosed untreated essential hypertension patients were not assessed.
Case-Control (n=160)
No
Effect estimate: AUC 0.899 (95% CI 0.854-0.945)
Absolute Event Rate: 498.54% vs 198.68%
p-value: p=<0.0001
Endothelial dysfunction is regarded as the initial lesion in the development of atherosclerosis. Endocan, previously called endothelial cell-specific molecule 1 (ESM-1), is a new candidate immunoinflammatory marker that may be associated with cardiometabolic risk factors. Therefore, we assessed serum levels of endocan in newly diagnosed patients with untreated essential hypertension (HT). A total of 18 patients with HT and 23 normotensive control participants were included in the study. Serum endocan levels, carotid intima-media thickness (cIMT), and high-sensitivity C-reactive protein (hsCRP) were measured. Serum endocan levels were significantly higher in the HT group (P < .001). In patients with HT, serum endocan levels correlated positively with cIMT and hsCRP (r = .551, P < .001 and r = .644, P < .001, respectively). Our findings suggest that circulating endocan levels represent a new marker in patients with essential HT. Endocan may be a surrogate endothelial dysfunction marker and may have a functional role in endothelium-dependent pathological disorders.
No takes yet. Share an insight, caveat, or question.
Balta et al. (2014) conducted a case-control in Venous Thromboembolism (VTE) (n=160). Elevated serum ESM1 (Endocan) levels vs. Healthy controls was evaluated on VTE diagnosis (Diagnostic accuracy of serum ESM1) (AUC 0.899, 95% CI 0.854-0.945, p=<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: